Physician profile
John Dudley Weaver
NPI 1841248408
$6,875.52
in general payments reported to CMS, 2019-2025
17 companies · $1,095 in 2025
The $1,095 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $430 · 2020: $650 · 2021: $724 · 2022: $1,479 · 2023: $948 · 2024: $1,549 · 2025: $1,095.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,591.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,315.02 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $2,029.76 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $563.21 | 2020-2024 | Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $372.37 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $369.27 | 2019-2022 | |
| Pfizer INC. | $236.39 | 2020-2025 | |
| Abbvie INC. | $210.01 | 2022-2023 | Vraylar |
| Antares Pharma, INC. | $158.81 | 2022-2024 | Xyosted |
| Biohaven Pharmaceutical Holding Company LTD. | $148.98 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.44 | 2020-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $116.63 | 2021-2022 | |
| Exact Sciences Corporation | $66.91 | 2023-2025 | Cologuard Collection Kit |
| Philips North America LLC | $55.95 | 2022-2023 | |
| Glaxosmithkline, LLC. | $51.78 | 2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $25.00 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $18.81 | 2022 | |
| Merck Sharp & Dohme LLC | $14.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Weaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.